

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION, the specification of which:

- is attached hereto.
- was filed on August 21, 1997 as Application Serial No. 08/915,918.
- and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)Priority Claimed

| (Number) | (Country) | (Day/Month/Year Filed) | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
|----------|-----------|------------------------|--------------------------|-------------------------------------|
| Yes      | No        |                        |                          |                                     |

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

|  |                                  |
|--|----------------------------------|
| 60/024,980<br>(Application Serial No.) | August 30, 1996<br>(Filing Date) |
|--|----------------------------------|

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

| (Application Serial No.) | (Filing Date) | (Status-patented, pending, abandoned) |
|--------------------------|---------------|---------------------------------------|
|--------------------------|---------------|---------------------------------------|

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's Signature

Date: 9/7/97

Full name of sole or first inventor

Suad Efendic

Residence

Stjarnvagen 16B, 18134 Lidingo, Sweden

Citizenship

SWEDEN

Post Office Address

Stjarnvagen 16B, 18134 Lidingo, Sweden

Inventor's Signature

Date:

Full name of second joint inventor, if any

\_\_\_\_\_

Residence

\_\_\_\_\_

Citizenship

\_\_\_\_\_

Post Office Address

\_\_\_\_\_

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200

BEST AVAILABLE COPY

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

By Valerie A. Wilson

ELI LILLY AND COMPANY

Date

February 17, 2000

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

|            |   |   |                           |
|------------|---|---|---------------------------|
| Applicants | : | Suad Efendic  | )                         |
| Serial No. | : | 08/915,918  | )                         |
| Filed      | : | August 21, 1997   | ) Group Art Unit:<br>1646 |
| For        | : | USE OF GLP-1 ANALOGS IN TREATMENT<br>OF MYOCARDIAL INFARCTION | ) Examiner:<br>Saoud, C.  |
| Docket No. | : | X-10822   | )                         |

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST  
(REVOCATION OF PRIOR POWERS)**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

I, Robert A. Armitage, Vice President and Patent Counsel, LRL Law of Eli Lilly and Company, am authorized to sign this Power of Attorney by Assignee of Entire Interest (Revocation of Prior Powers) on behalf of Eli Lilly and Company which is the Assignee of record of the Entire Interest of the above-identified patent.

The Assignee hereby revokes all powers of attorney previously given, and hereby appoints

BEST AVAILABLE COPY

| Attorney             | Reg. No. | Attorney              | Reg. No. |
|----------------------|----------|-----------------------|----------|
| Arvie J. Anderson    | 45,263   | Francis O. Giash      | 44,712   |
| Lynn D. Apelgren     | 45,341   | Edward P. Gray        | 30,638   |
| Robert A. Armitage   | 27,417   | Amy E. Hamilton       | 33,894   |
| Brian P. Barrett     | 39,597   | Suzanne M. Harvey     | 42,640   |
| Michael T. Bates     | 34,121   | Frederick D. Hunter   | 26,915   |
| Roger S. Benjamin    | 27,025   | Thomas E. Jackson     | 33,064   |
| William R. Boudreaux | 35,796   | Charles Joyner        | 30,466   |
| Steven P. Caltrider  | 36,467   | James J. Kelley       | 41,888   |
| Paul R. Cantrell     | 36,470   | Paul C. Kimball       | 34,641   |
| Charles E. Cohen     | 34,565   | Paul J. Koivuniemi    | 31,533   |
| Kenneth J. Collier   | 34,982   | Robert E. Lee         | 27,919   |
| Daniel W. Collins    | 31,912   | James P. Leeds        | 35,241   |
| Robert A. Conrad     | 32,089   | Nelsen L. Lentz       | 38,537   |
| Elizabeth A. Dawalt  | 44,646   | Ronald S. Maciak      | 35,262   |
| Paul R. Darkes       | 33,862   | Janet T. McClain      | 36,863   |
| Steven G. Davis      | 39,652   | Scott A. McNeil       | 37,185   |
| John C. Demeter      | 30,167   | Arlene K. Musser      | 37,895   |
| Manisha A. Desai     | 43,585   | Douglas K. Norman     | 33,267   |
| John H. Engelmann    | 28,075   | Arleen Palmberg       | 40,422   |
| Joanne Longo Feeney  | 35,134   | Raymond S. Parker III | 34,893   |
| Paul J. Gaylo        | 36,808   | Thomas G. Plant       | 35,784   |

Serial No. 08/915,918

|                    |         |                         |         |
|--------------------|---------|-------------------------|---------|
| James J. Sales     | 33,773  | MaCharri Vorndran-Jones | 36,711  |
| Michael J. Sayles  | 32,295  | Gilbert T. Voy          | 43,972  |
| Robert L. Sharp    | P45,609 | Andrea C. Walsh         | 34,988  |
| David M. Stemerick | 40,187  | Thomas D. Webster       | 39,872  |
| Mark J. Stewart    | 43,936  | Lawrence T. Welch       | 29,487  |
| Robert D. Titus    | 40,206  | Alexander Wilson        | P45,782 |
| Barbara Twardzik   | 36,386  |                         |         |

to prosecute and transact all business in the Patent and Trademark Office connected with the above-identified patent.


Please send correspondence in connection with this application to:

Eli Lilly and Company  
Patent Division/SGD  
Lilly Corporate Center  
Indianapolis, Indiana 46285.

ASSIGNMENT

[X] Recorded in PTO on December 1, 1997  
Reel 8846  
Frame 135

[ ] Assignment being submitted separately

ELI LILLY AND COMPANY  
  
By: Robert A. Armitage  
Vice President and Patent Counsel  
Phone: 317-433-5499

Eli Lilly and Company  
Patent Division/RAA  
Lilly Corporate Center  
Indianapolis, Indiana 46285

BEST AVAILABLE COPY